You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemsirolimus
Accession NumberDB06287
TypeSmall Molecule
GroupsApproved
DescriptionTemsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.
Structure
Thumb
Synonyms
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
Torisel
External Identifiers
  • CCI-779
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-temsirolimusSolution25 mgIntravenousGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
ToriselLiquid25 mgIntravenousPfizer2008-01-11Not applicableCanada
ToriselInjection, solution, concentrate30 mgIntravenousPfizer2007-11-19Not applicableEu
ToriselKitWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2007-07-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII624KN6GM2T
CAS number162635-04-3
WeightAverage: 1030.2871
Monoisotopic: 1029.602485741
Chemical FormulaC56H87NO16
InChI KeyCBPNZQVSJQDFBE-FUXHJELOSA-N
InChI
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
IUPAC Name
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
SMILES
OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[[email protected]](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[[email protected]](C)C[[email protected]](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[[email protected]]3C(=O)O2)C[[email protected]]1OC
Pharmacology
IndicationFor the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
Structured Indications
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentCancer, Advanced1
0RecruitingPreventionTumors, Solid1
1Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Prostate Cancers / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentCancer, Breast / Colon Cancer / Colon Neoplasms / Colonic Cancers / Kidney Cancer / Lung Cancers / Melanoma / Neoplasms, Breast1
1Active Not RecruitingTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Peritoneal Cancer1
1Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Hereditary Paraganglioma / Male Breast Cancer / Malignant Paraganglioma / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Pheochromocytoma / Pancreatic Polypeptide Tumor / Recurrent Breast Cancer / Recurrent Cervical Cancer / Recurrent Endometrial Carcinoma / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Recurrent Neuroendocrine Carcinoma of the Skin / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pheochromocytoma / Recurrent Prostate Cancer / Recurrent Renal Cell Cancer / Recurrent Small Cell Lung Cancer / Recurrent Uterine Sarcoma / Regional Gastrointestinal Carcinoid Tumor / Regional Pheochromocytoma / Stage III Cervical Cancer / Stage III Endometrial Carcinoma / Stage III Neuroendocrine Carcinoma of the Skin / Stage III Ovarian Epithelial Cancer / Stage III Ovarian Germ Cell Tumor / Stage III Prostate Cancer / Stage III Renal Cell Cancer / Stage III Uterine Sarcoma / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Breast Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Endometrial Carcinoma / Stage IV Neuroendocrine Carcinoma of the Skin / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Prostate Cancer / Stage IV Renal Cell Cancer / Stage IV Uterine Sarcoma / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer / Thyroid Gland Medullary Carcinoma1
1Active Not RecruitingTreatmentHepatocellular Carcinomas1
1Active Not RecruitingTreatmentPediatric Solid Tumors1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedNot AvailableHealthy1
1CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdult Solid Neoplasm / Lung Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Renal Cell Carcinoma / Recurrent Uterine Corpus Sarcoma / Stage III Renal Cell Cancer / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IV Renal Cell Cancer / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentBrain and Central Nervous System Tumors / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancer, Breast / Endometrial Cancers / Kidney Cancer / Lung Cancers / Lymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancers1
1CompletedTreatmentCancers / Renal Cell Cancer1
1CompletedTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma1
1CompletedTreatmentColorectal Adenocarcinoma / Colorectal Cancers1
1CompletedTreatmentEndometrial Papillary Serous Carcinoma / Recurrent Endometrial Carcinoma / Recurrent Renal Cell Cancer / Stage III Endometrial Carcinoma / Stage III Renal Cell Cancer / Stage IV Endometrial Carcinoma / Stage IV Renal Cell Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentGenital Neoplasms, Female1
1CompletedTreatmentHepatic Complications / Lymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentKidney Cancer1
1CompletedTreatmentKidney Cancer / Renal Cell Cancer1
1CompletedTreatmentMalignant Carcinoma / Neoplasms1
1CompletedTreatmentMelanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentOvarian Sarcoma / Ovarian Stromal Cancer / Recurrent Endometrial Carcinoma / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Stage III Endometrial Carcinoma / Stage III Ovarian Epithelial Cancer / Stage III Ovarian Germ Cell Tumor / Stage IV Endometrial Carcinoma / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRecurrent Adult Hodgkin's Lymphoma1
1CompletedTreatmentRecurrent Melanoma / Recurrent Renal Cell Cancer / Stage IV Melanoma / Stage IV Renal Cell Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRenal Cell Carcinoma (RCC)1
1CompletedTreatmentResistant Solid Malignancies2
1CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific2
1RecruitingTreatmentAdvanced Cancers2
1RecruitingTreatmentAdvanced/Recurrent Breast Cancer / Cancer, Ovarian / Endometrial Cancers1
1RecruitingTreatmentB-cell Lymphoma Refractory1
1RecruitingTreatmentCancer, Advanced3
1RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1RecruitingTreatmentCentral Nervous System / Recurrent Lymphoma / Refractory Lymphomas / Solid Tumours1
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentPatients With Advanced or Metastatic Solid Tumors1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia1
1TerminatedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentPancreatic Adenocarcinoma1
1WithdrawnBasic ScienceNeoplasms, Brain1
1WithdrawnTreatmentGliomas / Neoplasms, Brain Stem / Pinealoma1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Diffuse Astrocytoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Oligodendroglioma / Recurrent Adult Brain Neoplasm1
1, 2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentCognitive Side Effects of Cancer Therapy / Lethargy / Neurotoxicity Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Therapy-Related Toxicity / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentLymphoma NOS1
1, 2Active Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2CompletedTreatmentAdenocarcinomas / Neoplasms1
1, 2CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Diffuse Astrocytoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Adult Pilocytic Astrocytoma / Adult Pineal Gland Astrocytoma / Adult Subependymal Giant Cell Astrocytoma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2CompletedTreatmentInoperable HCC1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentProstate Cancers1
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentSarcomas1
1, 2RecruitingTreatmentCancer, Advanced / Carcinoma, Colorectal / Endometrial / Non Small Cell Lung Cancer (NSCLC) / Pancreatic Cancers / Renal Cell Cancer / Uterine1
1, 2TerminatedTreatmentAdvanced Cancers1
1, 2TerminatedTreatmentAndrogen-insensitive Prostate Cancer / Castrate-resistant Prostate Cancer (CRPC) / Hormone-Refractory Prostate Cancer / Metastatic Disease / Prostate Cancers / Prostatic Neoplasms1
1, 2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2WithdrawnTreatmentHepatocellular Carcinomas1
1, 2WithdrawnTreatmentMantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Endometrial Serous Adenocarcinoma / Localized Non-Resectable Adult Liver Carcinoma / Lung Carcinoid Tumor / Malignant Ovarian Mixed Epithelial Tumor / Malignant Pancreatic Gastrinoma / Malignant Pancreatic Glucagonoma / Malignant Pancreatic Insulinoma / Malignant Pancreatic Somatostatinoma / Metastatic Digestive System Neuroendocrine Tumor G1 / Ovarian Carcinosarcoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Pancreatic Alpha Cell Adenoma / Pancreatic Beta Cell Adenoma / Pancreatic Delta Cell Adenoma / Pancreatic G-Cell Adenoma / Pancreatic Polypeptide Tumor / Recurrent Adult Liver Carcinoma / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer / Uterine Carcinosarcoma1
2Active Not RecruitingTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma1
2Active Not RecruitingTreatmentAdvanced Rare Tumours1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
2Active Not RecruitingTreatmentChildhood Alveolar Soft-part Sarcoma / Childhood Angiosarcoma / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Gliosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Neurofibrosarcoma / Childhood Synovial Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Osteosarcoma1
2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2Active Not RecruitingTreatmentEndometrial Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC1 Uterine Corpus Cancer / Stage IIIC2 Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2Active Not RecruitingTreatmentHER2-mutant Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentHepatocellular Carcinomas1
2Active Not RecruitingTreatmentKidney Cancer / Renal Cell Carcinoma (RCC)1
2Active Not RecruitingTreatmentMale Breast Carcinoma / Recurrent Breast Carcinoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2Active Not RecruitingTreatmentRecurrent Endometrial Carcinoma1
2Active Not RecruitingTreatmentRecurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
2Active Not RecruitingTreatmentRelapsed Bladder Cancer1
2Active Not RecruitingTreatmentThyroid Cancers1
2CompletedNot AvailableEndometrioid Carcinoma / MTOR Protein1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdvanced Renal Cell Carcinoma1
2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Neoplasms, Malignant / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentCervical Adenocarcinoma / Cervical Adenosquamous Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Cell Carcinoma / Endometrial Clear Cell Carcinoma / Endometrial Papillary Serous Carcinoma / Recurrent Endometrial Carcinoma / Stage IIIA Endometrial Carcinoma / Stage IIIB Endometrial Carcinoma / Stage IIIC Endometrial Carcinoma / Stage IVA Endometrial Carcinoma / Stage IVB Endometrial Carcinoma1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer1
2CompletedTreatmentFallopian Tube Cancer / Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2CompletedTreatmentGastrointestinal Stromal Tumors / Recurrent Adult Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentGenital Diseases, Female / Neoplasms, Endometrial / Neoplasms, Ovarian / Ovarian Diseases1
2CompletedTreatmentGlioblastoma Multiforme1
2CompletedTreatmentLeukemias1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMetastatic Gastrointestinal Carcinoid Tumor / Pulmonary Carcinoid Tumor / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma1
2CompletedTreatmentMetastatic Osteosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Osteosarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentMultiple Sclerosis, Relapsing-Remitting1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentNon-clear Cell Renal Cell Cancer1
2CompletedTreatmentOvarian Clear Cell Cystadenocarcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2CompletedTreatmentProstate Cancers3
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
2CompletedTreatmentRecurrent Mantle Cell Lymphoma2
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentAcute Myeloblastic Leukemia1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Brain Tumor, Recurrent / Glioblastomas / Mixed Gliomas1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2RecruitingTreatmentKidney Cancer1
2RecruitingTreatmentLymphoma, Hodgkins1
2RecruitingTreatmentMetastatic Cancers1
2RecruitingTreatmentRecurrent or Refractory Primary CNS Lymphoma1
2RecruitingTreatmentRenal Cell Cancer1
2RecruitingTreatmentRenal Cell Carcinoma (RCC)1
2RecruitingTreatmentUnresectable or Metastatic Hepatocellular Carcinoma1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentKidney Cancer1
2TerminatedTreatmentLiver Cancer1
2TerminatedTreatmentMucosal Melanoma / Recurrent Melanoma / Stage IV Melanoma1
2TerminatedTreatmentMyelodysplastic Syndrome1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentProstate Cancers1
2TerminatedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Refractory Chronic Lymphocytic Leukemia1
2TerminatedTreatmentRecurrent Uterine Sarcoma / Uterine Carcinosarcoma1
2TerminatedTreatmentRheumatoid Arthritis (RA)1
2TerminatedTreatmentSquamous Cell Carcinoma (SCC)1
2WithdrawnTreatmentMelanoma / Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3CompletedTreatmentLymphoma NOS1
3CompletedTreatmentNeoplasms, Kidney / Renal Cell Carcinoma (RCC)1
3CompletedTreatmentRenal Cell Carcinoma (RCC)2
3RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3SuspendedTreatmentBotryoid-Type Embryonal Rhabdomyosarcoma / Rhabdomyosarcoma, Alveolar / Rhabdomyosarcoma, Embryonal / Rhabdomyosarcomas / Sclerosing Rhabdomyosarcoma / Spindle Cell Rhabdomyosarcoma / Untreated Childhood Rhabdomyosarcoma1
4RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
4WithdrawnNot AvailableRenal Cell Carcinoma (RCC)1
Not AvailableCompletedNot AvailableRenal Cell Carcinoma (RCC)2
Not AvailableCompletedNot AvailableSquamous Cell Carcinoma (SCC)1
Not AvailableCompletedPreventionProstatic Neoplasms1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Metastatic Cancers1
Not AvailableCompletedTreatmentRenal Cell Carcinoma (RCC)1
Not AvailableRecruitingNot AvailableCarcinoma, Renal Cell, Advanced / Gastrointestinal Stroma Tumors / Lymphoma, Mantle-Cell1
Not AvailableWithdrawnTreatmentHead and Neck Cancers1
PharmacodynamicsNot Available
Mechanism of actionTemsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Serine/threonine-protein kinase mTORProteinyes
inhibitor
HumanP42345 details
Related Articles
AbsorptionInfused intravenous over 30 - 60 minutes. Cmax is typically observed at the end of infusion
Volume of distribution

172 L in whole blood of cancer patients; both temsirolimus and sirolimus are extensive distributed partitioned into formed blood elements

Protein binding87% bound to plasma proteins in vitro at a concentration of 100 ng/ml
Metabolism

Primarily metabolized by cytochrome P450 3A4 in the human liver. Sirolimus, an equally potent metabolite, is the primary metabolite in humans following IV infusion. Other metabolic pathways observed in in vitro temsirolimus metabolism studies include hydroxylation, reduction and demethylation.

SubstrateEnzymesProduct
Temsirolimus
Not Available
SirolimusDetails
Route of eliminationExcreted predominantly in feces (76%), 4.6% of drug and metabolites recovered in urine. 17% of drug was not recovered by either route following a 14-day sample collection.
Half lifeTemsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.
Clearance

16.2 L/h (22%)

ToxicityTemsirolimus has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of temsirolimus greater than 25 mg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Temsirolimus.Experimental
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Temsirolimus.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe risk or severity of adverse effects can be increased when 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE is combined with Temsirolimus.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Temsirolimus.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Temsirolimus.Approved
AcetaminophenThe serum concentration of Temsirolimus can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Temsirolimus.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Temsirolimus.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Temsirolimus.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Temsirolimus.Experimental
AlbendazoleThe serum concentration of Temsirolimus can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Temsirolimus can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Temsirolimus can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Temsirolimus.Approved, Investigational
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temsirolimus.Approved
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Temsirolimus.Approved
ALT-110The risk or severity of adverse effects can be increased when Temsirolimus is combined with ALT-110.Investigational
AmantadineThe serum concentration of Temsirolimus can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Temsirolimus.Approved, Investigational
Aminohippuric acidThe serum concentration of Temsirolimus can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Temsirolimus can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Temsirolimus can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Temsirolimus can be increased when it is combined with Amlodipine.Approved
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Temsirolimus.Approved
AmsacrineThe serum concentration of Temsirolimus can be increased when it is combined with Amsacrine.Approved
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Temsirolimus.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Temsirolimus.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Temsirolimus.Approved
AprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Temsirolimus.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Temsirolimus.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Temsirolimus.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Temsirolimus.Approved, Investigational
AstemizoleThe serum concentration of Temsirolimus can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Temsirolimus.Approved, Investigational
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Temsirolimus.Approved, Investigational
AtenololThe serum concentration of Temsirolimus can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Temsirolimus can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Temsirolimus can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Temsirolimus.Approved, Investigational
AzelastineThe serum concentration of Temsirolimus can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Temsirolimus can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Temsirolimus.Investigational
BatimastatThe risk or severity of adverse effects can be increased when Batimastat is combined with Temsirolimus.Experimental
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Temsirolimus.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Temsirolimus.Approved, Investigational
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Temsirolimus.Experimental
BenzocaineThe serum concentration of Temsirolimus can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Temsirolimus can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
BexaroteneThe serum concentration of Temsirolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The risk or severity of adverse effects can be increased when Bi201335 is combined with Temsirolimus.Investigational
BiperidenThe serum concentration of Temsirolimus can be increased when it is combined with Biperiden.Approved
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.Approved, Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Temsirolimus.Approved
BortezomibThe metabolism of Temsirolimus can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Temsirolimus can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Temsirolimus.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.Approved
BromocriptineThe serum concentration of Temsirolimus can be increased when it is combined with Bromocriptine.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Temsirolimus.Withdrawn
BuprenorphineThe serum concentration of Temsirolimus can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Temsirolimus can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temsirolimus.Approved
CaffeineThe serum concentration of Temsirolimus can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Temsirolimus.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Temsirolimus.Approved
CandesartanThe serum concentration of Temsirolimus can be increased when it is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Temsirolimus.Experimental
CandoxatrilatThe risk or severity of adverse effects can be increased when Candoxatrilat is combined with Temsirolimus.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Temsirolimus.Approved
CarbamazepineThe serum concentration of Temsirolimus can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Temsirolimus.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Temsirolimus.Approved
CarvedilolThe serum concentration of Temsirolimus can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Temsirolimus can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Temsirolimus.Experimental
CDX-110The risk or severity of adverse effects can be increased when Temsirolimus is combined with CDX-110.Investigational
CeritinibThe serum concentration of Temsirolimus can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Temsirolimus.Withdrawn
ChloroquineThe serum concentration of Temsirolimus can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Temsirolimus can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Temsirolimus can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Temsirolimus can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Temsirolimus.Experimental
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Temsirolimus.Experimental
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Temsirolimus.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Temsirolimus.Approved
CimetidineThe serum concentration of Temsirolimus can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Temsirolimus.Approved
CitalopramThe serum concentration of Temsirolimus can be increased when it is combined with Citalopram.Approved
ClarithromycinThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Temsirolimus.Approved
ClemastineThe metabolism of Temsirolimus can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Temsirolimus.Approved, Illicit
ClofazimineThe serum concentration of Temsirolimus can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Temsirolimus.Approved, Investigational
ClomipramineThe serum concentration of Temsirolimus can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Temsirolimus.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Temsirolimus.Approved, Nutraceutical
ClotrimazoleThe metabolism of Temsirolimus can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Clozapine.Approved
CobicistatThe metabolism of Temsirolimus can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Temsirolimus.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Temsirolimus.Approved
ColforsinThe serum concentration of Temsirolimus can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Temsirolimus can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Temsirolimus.Approved
CrizotinibThe metabolism of Temsirolimus can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Temsirolimus can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.Approved
DabrafenibThe serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Temsirolimus can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Temsirolimus can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Temsirolimus.Approved
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Temsirolimus.Approved
DasatinibThe serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Temsirolimus can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Temsirolimus.Approved
DeferasiroxThe serum concentration of Temsirolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Temsirolimus can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Temsirolimus.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Temsirolimus.Investigational
DesipramineThe serum concentration of Temsirolimus can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Temsirolimus.Approved
DesloratadineThe serum concentration of Temsirolimus can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Temsirolimus can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Temsirolimus can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Temsirolimus.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Temsirolimus can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Temsirolimus.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
DihydroergotamineThe metabolism of Temsirolimus can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Temsirolimus.Illicit
DiltiazemThe metabolism of Temsirolimus can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Temsirolimus can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Temsirolimus.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Temsirolimus can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Temsirolimus can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Temsirolimus.Approved, Investigational
DoxorubicinThe serum concentration of Temsirolimus can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Temsirolimus can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Temsirolimus can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Temsirolimus can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Temsirolimus.Approved
EcabetThe risk or severity of adverse effects can be increased when Ecabet is combined with Temsirolimus.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Temsirolimus.Approved
EfavirenzThe serum concentration of Temsirolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Temsirolimus.Investigational
ElbasvirThe serum concentration of Temsirolimus can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Temsirolimus.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Temsirolimus.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Temsirolimus.Approved
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Temsirolimus.Experimental
EnzalutamideThe serum concentration of Temsirolimus can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Temsirolimus.Approved, Investigational
ErgonovineThe serum concentration of Temsirolimus can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Temsirolimus can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Temsirolimus.Approved, Investigational
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Temsirolimus.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Temsirolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Temsirolimus.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Temsirolimus can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Temsirolimus can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Temsirolimus can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Temsirolimus.Approved
EtoposideThe serum concentration of Temsirolimus can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Temsirolimus can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Temsirolimus.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Temsirolimus.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Temsirolimus.Approved
FelodipineThe serum concentration of Temsirolimus can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Temsirolimus can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.Approved
FexofenadineThe serum concentration of Temsirolimus can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Temsirolimus.Approved
FingolimodTemsirolimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Fluconazole.Approved
FluoxetineThe serum concentration of Temsirolimus can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Temsirolimus can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Temsirolimus can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Temsirolimus can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Temsirolimus.Approved
FluvoxamineThe metabolism of Temsirolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Temsirolimus.Approved
FosaprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Temsirolimus.Approved
FosphenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Temsirolimus is combined with G17DT.Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Temsirolimus.Investigational
GefitinibThe serum concentration of Temsirolimus can be increased when it is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Geldanamycin is combined with Temsirolimus.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Temsirolimus.Approved
GenisteinThe serum concentration of Temsirolimus can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Temsirolimus is combined with GI-5005.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Temsirolimus.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Temsirolimus.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Temsirolimus.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Temsirolimus.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Temsirolimus.Approved
GlyburideThe serum concentration of Temsirolimus can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Temsirolimus can be increased when it is combined with Glycerol.Experimental
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Temsirolimus.Experimental
Gramicidin DThe serum concentration of Temsirolimus can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Temsirolimus.Approved
GrepafloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Temsirolimus.Investigational
HaloperidolThe serum concentration of Temsirolimus can be increased when it is combined with Haloperidol.Approved
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Temsirolimus.Experimental
HydrocortisoneThe serum concentration of Temsirolimus can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Temsirolimus.Approved
IdelalisibThe serum concentration of Temsirolimus can be increased when it is combined with Idelalisib.Approved
idraparinuxThe risk or severity of adverse effects can be increased when idraparinux is combined with Temsirolimus.Investigational
ImatinibThe metabolism of Temsirolimus can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Temsirolimus.Investigational
ImipramineThe serum concentration of Temsirolimus can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Temsirolimus.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Temsirolimus.Approved
IndomethacinThe serum concentration of Temsirolimus can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Temsirolimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Temsirolimus is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Temsirolimus.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Temsirolimus.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Temsirolimus.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Temsirolimus.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Temsirolimus.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Temsirolimus.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Temsirolimus.Approved, Investigational
IsavuconazoniumThe metabolism of Temsirolimus can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Temsirolimus.Approved, Withdrawn
IsradipineThe metabolism of Temsirolimus can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Temsirolimus can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Temsirolimus can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe risk or severity of adverse effects can be increased when Ixazomib is combined with Temsirolimus.Approved
JosamycinThe risk or severity of adverse effects can be increased when Josamycin is combined with Temsirolimus.Approved
KetamineThe serum concentration of Temsirolimus can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Temsirolimus.Approved
KetoconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Temsirolimus can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Temsirolimus.Experimental
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Temsirolimus.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Temsirolimus.Approved, Investigational
LansoprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Temsirolimus can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Temsirolimus.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Temsirolimus.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Temsirolimus.Approved
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Temsirolimus.Approved, Investigational
LevofloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Temsirolimus.Approved
LevothyroxineThe serum concentration of Temsirolimus can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Temsirolimus can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Temsirolimus.Approved
LiothyronineThe serum concentration of Temsirolimus can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Temsirolimus can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Temsirolimus.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus.Approved, Investigational
LomitapideThe serum concentration of Temsirolimus can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Temsirolimus can be increased when it is combined with Loperamide.Approved
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Temsirolimus.Approved
LoratadineThe serum concentration of Temsirolimus can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Temsirolimus can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Temsirolimus can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Temsirolimus can be decreased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Temsirolimus.Approved, Investigational
MaprotilineThe serum concentration of Temsirolimus can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Temsirolimus can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Temsirolimus can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Temsirolimus can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Temsirolimus can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temsirolimus.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.Approved
MethadoneThe serum concentration of Temsirolimus can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Temsirolimus.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Temsirolimus.Approved, Investigational
MibefradilThe serum concentration of Temsirolimus can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Temsirolimus can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Temsirolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Temsirolimus.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Temsirolimus.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Temsirolimus.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
MitomycinThe serum concentration of Temsirolimus can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Temsirolimus can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Temsirolimus can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Temsirolimus can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Temsirolimus.Approved
MorphineThe serum concentration of Temsirolimus can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Temsirolimus.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Temsirolimus.Experimental
NadololThe serum concentration of Nadolol can be increased when it is combined with Temsirolimus.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Temsirolimus.Investigational
NafcillinThe serum concentration of Temsirolimus can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Temsirolimus.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
NaltrexoneThe serum concentration of Temsirolimus can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Temsirolimus can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Temsirolimus.Investigational
NefazodoneThe metabolism of Temsirolimus can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Temsirolimus.Approved
NeostigmineThe serum concentration of Temsirolimus can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Temsirolimus can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Temsirolimus can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Temsirolimus can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Temsirolimus can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Temsirolimus can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Temsirolimus.Approved
NisoldipineThe serum concentration of Temsirolimus can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Temsirolimus can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Temsirolimus.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Temsirolimus.Approved
NorethisteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Temsirolimus.Approved, Investigational
OlaparibThe metabolism of Temsirolimus can be decreased when combined with Olaparib.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Temsirolimus.Vet Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Temsirolimus.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Temsirolimus.Approved
OmeprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Temsirolimus can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Temsirolimus.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Temsirolimus.Approved
P-NitrophenolThe serum concentration of Temsirolimus can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temsirolimus.Approved, Vet Approved
PalbociclibThe serum concentration of Temsirolimus can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Temsirolimus.Approved, Investigational
PantoprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Temsirolimus can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.Approved
PentobarbitalThe metabolism of Temsirolimus can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Temsirolimus.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Temsirolimus.Approved, Withdrawn
PhenobarbitalThe metabolism of Temsirolimus can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Temsirolimus.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temsirolimus.Approved, Investigational
PimozideThe serum concentration of Temsirolimus can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Temsirolimus.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Temsirolimus.Approved
Platelet Activating FactorThe serum concentration of Temsirolimus can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Temsirolimus.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Temsirolimus.Approved
PosaconazoleThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Temsirolimus.Approved, Investigational
PravastatinThe serum concentration of Temsirolimus can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Temsirolimus can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Temsirolimus.Approved, Vet Approved
PrednisoneThe serum concentration of Temsirolimus can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Temsirolimus can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Temsirolimus.Investigational
ProbenecidThe serum concentration of Temsirolimus can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Temsirolimus can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Temsirolimus can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Temsirolimus can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Temsirolimus can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Temsirolimus.Approved
QuercetinThe serum concentration of Temsirolimus can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Temsirolimus.Approved
QuinacrineThe serum concentration of Temsirolimus can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Temsirolimus.Approved, Investigational
QuinidineThe serum concentration of Temsirolimus can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Temsirolimus can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Temsirolimus.Approved
RacecadotrilThe risk or severity of adverse effects can be increased when Racecadotril is combined with Temsirolimus.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Temsirolimus.Approved
RanitidineThe serum concentration of Temsirolimus can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Temsirolimus.Approved, Investigational
ReboxetineThe serum concentration of Temsirolimus can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Temsirolimus can be increased when it is combined with Regorafenib.Approved
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Temsirolimus.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Temsirolimus.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Temsirolimus can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Temsirolimus can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Temsirolimus.Approved, Investigational
RilpivirineThe serum concentration of Temsirolimus can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Temsirolimus.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Temsirolimus.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Temsirolimus.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Temsirolimus.Approved
RolapitantThe serum concentration of Temsirolimus can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Temsirolimus.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Temsirolimus.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Temsirolimus.Approved, Vet Approved
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Temsirolimus.Approved, Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Temsirolimus.Approved
ScopolamineThe serum concentration of Temsirolimus can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Temsirolimus can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Temsirolimus.Approved
SertralineThe serum concentration of Temsirolimus can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Temsirolimus can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Temsirolimus.Approved
SiltuximabThe serum concentration of Temsirolimus can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Temsirolimus.Approved
SimvastatinThe serum concentration of Temsirolimus can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temsirolimus.Approved
SirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Temsirolimus.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Temsirolimus.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Temsirolimus.Investigational
SorafenibThe serum concentration of Temsirolimus can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Temsirolimus.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Temsirolimus.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Temsirolimus.Approved
SpironolactoneThe serum concentration of Temsirolimus can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Temsirolimus is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Temsirolimus can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Temsirolimus can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Temsirolimus can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Temsirolimus can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Temsirolimus can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Temsirolimus can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Temsirolimus.Approved, Investigational
SumatriptanThe serum concentration of Temsirolimus can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Temsirolimus can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus.Approved, Investigational
TacrolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Temsirolimus can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Temsirolimus.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Temsirolimus.Approved
TelithromycinThe risk or severity of adverse effects can be increased when Telithromycin is combined with Temsirolimus.Approved
TelmisartanThe serum concentration of Temsirolimus can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Temsirolimus.Experimental, Investigational
TerazosinThe serum concentration of Temsirolimus can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Temsirolimus can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Temsirolimus can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Temsirolimus can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Temsirolimus is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Temsirolimus.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Temsirolimus.Approved
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Temsirolimus.Experimental
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Temsirolimus.Approved
TiclopidineThe metabolism of Temsirolimus can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Temsirolimus.Approved
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Temsirolimus.Approved, Investigational
TocilizumabThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTemsirolimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Temsirolimus.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Temsirolimus.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Temsirolimus.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Temsirolimus.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Temsirolimus.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Temsirolimus.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Temsirolimus.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Temsirolimus.Approved
TrazodoneThe serum concentration of Temsirolimus can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Temsirolimus can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Temsirolimus can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Temsirolimus can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Temsirolimus can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Temsirolimus.Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Troleandomycin is combined with Temsirolimus.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Temsirolimus.Vet Approved
UbenimexThe risk or severity of adverse effects can be increased when Ubenimex is combined with Temsirolimus.Experimental
UlinastatinThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Temsirolimus.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Temsirolimus.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Temsirolimus.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Temsirolimus.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Temsirolimus.Approved
VenlafaxineThe metabolism of Temsirolimus can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Temsirolimus can be decreased when combined with Verapamil.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temsirolimus.Approved, Investigational
VinblastineThe serum concentration of Temsirolimus can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Temsirolimus.Approved, Investigational
VincristineThe serum concentration of Temsirolimus can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Temsirolimus can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Temsirolimus.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Temsirolimus.Approved, Investigational
VoriconazoleThe metabolism of Temsirolimus can be decreased when combined with Voriconazole.Approved, Investigational
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Temsirolimus.Approved, Investigational, Withdrawn
Ym150The risk or severity of adverse effects can be increased when Ym150 is combined with Temsirolimus.Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Temsirolimus.Approved
ZimelidineThe serum concentration of Temsirolimus can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Temsirolimus can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Kwang-Chung Lee, Ting-Huei Lee, Yen-Shih Tung, Chia-Chen Kao, Tzu-Ai Lee, “Process for preparation of temsirolimus.” U.S. Patent US20100249415, issued September 30, 2010.

US20100249415
General References
  1. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L: Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. 2007 Nov;47(11):1430-9. Epub 2007 Oct 3. [PubMed:17913896 ]
External Links
ATC CodesL01XE09
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (402 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8908
Blood Brain Barrier-0.9494
Caco-2 permeable-0.664
P-glycoprotein substrateSubstrate0.8122
P-glycoprotein inhibitor IInhibitor0.8098
P-glycoprotein inhibitor IIInhibitor0.7467
Renal organic cation transporterNon-inhibitor0.7636
CYP450 2C9 substrateNon-substrate0.8699
CYP450 2D6 substrateNon-substrate0.8845
CYP450 3A4 substrateSubstrate0.7533
CYP450 1A2 substrateNon-inhibitor0.9126
CYP450 2C9 inhibitorNon-inhibitor0.8957
CYP450 2D6 inhibitorNon-inhibitor0.942
CYP450 2C19 inhibitorNon-inhibitor0.9155
CYP450 3A4 inhibitorNon-inhibitor0.9558
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9398
Ames testNon AMES toxic0.6087
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable0.9522
Rat acute toxicity2.8760 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9703
hERG inhibition (predictor II)Non-inhibitor0.7479
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous25 mg
Injection, solution, concentrateIntravenous30 mg
Kit
LiquidIntravenous25 mg
Prices
Unit descriptionCostUnit
Torisel 25 mg kit1467.89USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2187024 No2004-08-102015-04-14Canada
CA2429020 No2009-05-262021-11-13Canada
US5362718 Yes1999-08-152019-08-15Us
US8026276 Yes2006-07-202026-07-20Us
US8299116 Yes2004-01-252024-01-25Us
US8455539 Yes2004-01-252024-01-25Us
US8722700 Yes2004-01-252024-01-25Us
US8791097 Yes2012-11-102032-11-10Us
USRE44768 Yes1999-08-152019-08-15Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00235 mg/mLALOGPS
logP4.39ALOGPS
logP7.13ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area241.96 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity277.07 m3·mol-1ChemAxon
Polarizability112.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Alpha-amino acid ester
  • Macrolide
  • Alpha-amino acid or derivatives
  • Beta-hydroxy acid
  • Dicarboxylic acid or derivatives
  • Hydroxy acid
  • Oxane
  • Piperidine
  • Tertiary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid ester
  • Hemiacetal
  • Ketone
  • Lactam
  • Lactone
  • Cyclic ketone
  • Secondary alcohol
  • Carboxylic acid derivative
  • Organoheterocyclic compound
  • Azacycle
  • Oxacycle
  • Dialkyl ether
  • Ether
  • Carbonyl group
  • Organic oxide
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Organopnictogen compound
  • Alcohol
  • Primary alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Patard JJ, Pouessel D, Bensalah K, Culine S: Targeted therapy in renal cell carcinoma. World J Urol. 2008 Apr;26(2):135-40. doi: 10.1007/s00345-008-0237-4. Epub 2008 Feb 12. [PubMed:18265991 ]
  2. Radulovic S, Bjelogrlic SK: Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON. 2007 Sep;12 Suppl 1:S151-62. [PubMed:17935273 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:22 / Updated on January 17, 2017 03:56